Thus the aim of this study was to evaluate the prognostic value of the new liver function assessment tool, the albumin–bilirubin (ALBI) grade, in patients with hepatocellular carcinoma undergoing TACE. The gene discussed is ALB; the disease is hepatocellular carcinoma.